Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
about
Pathogenesis of human immunodeficiency virus infectionSubstrate requirements of hepatitis C virus serine proteinase for intermolecular polypeptide cleavage in Escherichia coliPotent HIV-1 protease inhibitors incorporating meso-bicyclic urethanes as P2-ligands: structure-based design, synthesis, biological evaluation and protein–ligand X-ray studiesX-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitorIn vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinationsHuman immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cellsPotent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating eventCopper inhibits the protease from human immunodeficiency virus 1 by both cysteine-dependent and cysteine-independent mechanismsStructure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 proteaseAn inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infectionGeneration and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitorCGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activityAntiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue cultureIn vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatineInhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteinsTargets of a protease inhibitor, KNI-272, in HIV-1-infected cells.Genetic selection of poliovirus 2Apro-binding peptidesbeta-Galactosidase containing a human immunodeficiency virus protease cleavage site is cleaved and inactivated by human immunodeficiency virus proteaseAntimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase.Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments.Isolation of peptide aptamers that inhibit intracellular processes.Correlations between the in vitro and in vivo activity of anti-HIV agents: implications for future drug development.Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys.Inhibition of human and simian immunodeficiency virus protease function by targeting Vpx-protease-mutant fusion protein into viral particlesDrug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH.Proteolytic activity of novel human immunodeficiency virus type 1 proteinase proteins from a precursor with a blocking mutation at the N terminus of the PR domain.Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase.The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency.Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles.A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein.Tightly bound zinc in human immunodeficiency virus type 1, human T-cell leukemia virus type I, and other retroviruses.Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavageMutational analysis of a native substrate of the human immunodeficiency virus type 1 proteinaseExpression of virus-encoded proteinases: functional and structural similarities with cellular enzymesHIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity.HIV-1 protease as a potential target for anti-AIDS therapy.Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.Four Amino Acid Changes in HIV-2 Protease Confer Class-Wide Sensitivity to Protease Inhibitors.
P2860
Q24634681-26476A9E-B890-438D-8E9C-994C4DB42498Q27486002-C06B670E-59AE-4421-B8DC-A0022906E36BQ27652460-4EBC9F76-9657-475B-8EBE-DC188301C67BQ27678325-CADF5D6F-AAD1-479C-BF8D-8BA4403D1508Q28318476-5E65993C-5893-4AF7-8E4B-2BD805FBD8EAQ28318483-3C2DC57E-6468-48D8-8518-4502ADCAD386Q28320362-4A20E77D-535C-4DF4-B668-D9A7F9D3537BQ28328454-E545653B-306B-4159-A40A-2504B1EE5102Q28331230-47A74058-9EEF-45A0-8085-CB8AA3361E1AQ28331494-CF940839-078A-46C1-A6E2-5B0010DD0FE6Q28378387-6BB31D99-FD7D-4E4B-AC95-69FC36E412A8Q28378396-4ABE9E65-4753-4B68-827D-6E5CBB1D7257Q28378612-75271BB4-DD38-4E9E-997A-BA963841808AQ28378709-833B0834-F8B6-4674-8702-CCD2B53E2F45Q28379468-8898D5FC-7B96-4A07-96BD-1CDC24240ED5Q31912488-98001151-2C28-4CDD-83AA-1548FF36FEE1Q31957787-29DCD447-2D38-4391-985E-C07CB5337C1FQ33927954-C3CEDAEC-864B-49DB-A029-3E8DFC84F232Q34207289-E6E37754-EE01-4849-A935-138DE88F76A1Q34340138-0EDEDFB3-BD64-4B1D-B6AF-469DEAE49BBDQ34618267-2DA8E775-80E2-4BBE-8643-A0C24C2DAB52Q35052108-F1268178-1585-46C9-B832-109E77A65C13Q35174403-29EFE926-DFB9-4136-A811-A29D4C5B4848Q35325810-7C692510-F33E-4292-BC44-7B90BDB0E606Q35821454-6EA7D80F-D7AA-4E36-9A95-7F8450FB2784Q35860937-14BDE6BD-2B42-4A77-A949-1DC9D5ACD75CQ36281663-5D57BD8E-C8B5-4756-B44F-9180886891D0Q36619495-5E8AAB63-ABDE-47FA-A2A3-44393FA1C84CQ36626593-71D87198-7160-4666-82E6-C8E17062A766Q36636632-FF55503B-24E4-41AD-9797-C81E47CC9BD6Q36650046-26BCDE04-A37B-4A16-A230-8E628F218064Q36682122-831653B5-FD24-47B1-9DDE-72D1B9F7E578Q36690493-894FCC33-BCD4-4BB4-93EE-4EC632B22665Q36698832-A3865A3B-69A1-4A2E-AEBA-B449FB5839B4Q36812551-FB4B7FA8-7B08-4713-9301-29ED429B0355Q37059742-FC7BBF3B-95CB-4EB6-BA60-D05A9C73E1EDQ37447762-C2F9B8DE-CCEF-4676-81F3-F1C58FB70468Q37783047-AAF701E2-FEFA-4E41-B564-9A06EEDBCCCEQ38334320-3B72A9F6-F2D3-4471-9DCF-9FCECF11289DQ38820118-E933B8DA-C275-457C-9EFF-2BC9C32FAA95
P2860
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
description
1990 nî lūn-bûn
@nan
1990 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@ast
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@en
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@nl
type
label
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@ast
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@en
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@nl
prefLabel
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@ast
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@en
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@nl
P2093
P356
P1433
P1476
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues
@en
P2093
D M Lambert
G B Dreyer
J E Strickler
L J Hyland
T A Tomaszek
T J Matthews
P2888
P356
10.1038/343090A0
P407
P577
1990-01-04T00:00:00Z
P6179
1014472614